- Trials with a EudraCT protocol (255)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
255 result(s) found for: Imatinib.
Displaying page 1 of 13.
| EudraCT Number: 2012-002540-25 | Sponsor Protocol Number: CSTI571A2406 | Start Date*: 2013-02-19 |
| Sponsor Name:Novartis Pharma Services AG | ||
| Full Title: An open label, multi-center imatinib roll-over protocol for patients who have completed a previous Novartis sponsored imatinib study and are judged by the investigator to benefit from continued ima... | ||
| Medical condition: Male and female patients who are currently enrolled in a Novartis-sponsored, Oncology OGD&GMA imatinib study, are benefiting from treatment with imatinib and have fulfilled all their requirements ... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: FI (Completed) GB (GB - no longer in EU/EEA) FR (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2010-019568-35 | Sponsor Protocol Number: OPTIM IMATINIB | Start Date*: 2010-06-14 |
| Sponsor Name:CH VERSAILLES | ||
| Full Title: A prospective randomized phase II study evaluating the monitoring of imatinib mesylate (Gliveec®) plasmatic through level in patients newly diagnosed with chronic phase chronic myelogenous leukaemi... | ||
| Medical condition: Chronic Phase Chronic myelogenous leukemia (CP CML) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-004758-34 | Sponsor Protocol Number: CAMN107G2301 | Start Date*: 2009-03-13 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A randomized, open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tu... | |||||||||||||
| Medical condition: adult patients with histologically confirmed unresectable or metastatic GIST, either who have not received any prior anti-neoplastic therapy or, who experienced recurrence of GIST > 6 months after ... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) ES (Completed) SK (Completed) CZ (Completed) SE (Completed) HU (Completed) NL (Completed) DE (Completed) FR (Completed) IT (Completed) GB (Completed) DK (Prematurely Ended) GR (Prematurely Ended) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001251-41 | Sponsor Protocol Number: P20/05 | Start Date*: 2020-04-17 | |||||||||||
| Sponsor Name:CH de Versailles | |||||||||||||
| Full Title: A PROOF OF CONCEPT STUDY TESTING THE VALUE OF IMATINIB IN PREVENTION OF COVID-19 IN AGED PATIENTS. | |||||||||||||
| Medical condition: Aged patients at risk of COVID-19 infection | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2004-002601-69 | Sponsor Protocol Number: CA180-013 | Start Date*: 2005-01-25 |
| Sponsor Name:Bristol Myers Squibb International Corporation | ||
| Full Title: A Phase II Study to Determine the Activity of BMS-354825 in Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease that is Resistant to High Dose Ima... | ||
| Medical condition: Chronic phase Philadelphia chromosome-positive chronic myeloid leukemia | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) DE (Completed) SE (Completed) FI (Completed) GB (Completed) IE (Completed) IT (Completed) BE (Completed) ES (Completed) DK (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-003965-11 | Sponsor Protocol Number: CC-TT-IMA-14 | Start Date*: 2015-11-18 |
| Sponsor Name:University Medical Center Utrecht | ||
| Full Title: Targeted therapy with Imatinib for treatment of poor prognosis mesenchymal-type resectable colon cancer: a proof-of-concept study in the preoperative window period. | ||
| Medical condition: colon cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-001594-24 | Sponsor Protocol Number: CABL001E2201 | Start Date*: 2018-10-17 | |||||||||||
| Sponsor Name:Novartis Pharma AG | |||||||||||||
| Full Title: A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treat... | |||||||||||||
| Medical condition: Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with imatinib and have not achieved deep molecular response | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) PT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) PL (Completed) DK (Completed) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-006239-44 | Sponsor Protocol Number: NL37603.042.11 | Start Date*: 2012-10-02 |
| Sponsor Name:Dutch Childhood Oncology Group | ||
| Full Title: An international collaborative study to discontinue Imatinib/Glivec® in pediatric CML patients with sustained complete molecular response (STOPIMAPED) | ||
| Medical condition: Chronic Myeloid Leukemia pediatric patients treated with Imatinib having achieved and maintained complete molecular remission for at least 2 years. | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: NL (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-002170-36 | Sponsor Protocol Number: 2014-002170-36 | Start Date*: 2015-02-11 |
| Sponsor Name:Karolinska University Hospital | ||
| Full Title: Treatment of Cervical Spinal Cord Injury with Imatinib – a safety and feasibility study | ||
| Medical condition: Cervical Spinal Cord Injury | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2004-002504-15 | Sponsor Protocol Number: NordCML002 | Start Date*: 2004-12-01 |
| Sponsor Name:The Nordic CML Study Group | ||
| Full Title: A RANDOMIZED PHASE II STUDY COMPARING IMATINIB AND THE COMBINATION OF IMATINIB AND PEGYLATED INTERFERON ALPHA-2B IN NEWLY DIAGNOSED NON-HIGH RISK CHRONIC MYELOID LEUKEMIA PATIENTS IN COMPLETE HEMAT... | ||
| Medical condition: Newly diagnosed chronic myeloid leukemia (CML) belonging to intermedia (IR) or low risk (LR) by the Sokal prognostic score | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FI (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-001430-19 | Sponsor Protocol Number: ET21-084 | Start Date*: 2021-07-08 |
| Sponsor Name: Centre Léon Berard | ||
| Full Title: GIST-TEN: Randomized, prospective, multicentre, open label phase II study evaluating the interest of imatinib (Glivec) treatment maintenance or interruption after at least 10 years of treatment in ... | ||
| Medical condition: locally advanced or metastatic Gastrointestinal Stromal Tumors | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-005200-19 | Sponsor Protocol Number: I-CONIC | Start Date*: 2022-05-09 |
| Sponsor Name:Västra Götalandsregionen/Onkologiska kliniken | ||
| Full Title: Use of Imatinib to convert triple negative breast cancer into ER-positive breast cancer - "I-CONIC" | ||
| Medical condition: Early Triple Negative Breast Cancer planned for surgery. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-005047-26 | Sponsor Protocol Number: CAMN107A2302 | Start Date*: 2007-10-15 |
| Sponsor Name:Novartis Pharma Services | ||
| Full Title: A phase III multi-center, open-label, randomized study of the efficacy of nilotinib versus imatinib in adult patients with Philadelphia chromosome positive (Ph+ ) chronic myelogenous leukemia in ... | ||
| Medical condition: Nilotinib will be evaluated in patients having showed a suboptimal cytogenetic response to imatinib | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) CZ (Prematurely Ended) ES (Completed) DE (Completed) IT (Prematurely Ended) NL (Prematurely Ended) HU (Prematurely Ended) FR (Completed) GR (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-004774-24 | Sponsor Protocol Number: CSTI571BDE57 | Start Date*: 2006-03-09 |
| Sponsor Name:Novartis Pharma GmbH | ||
| Full Title: An open-label multicenter phase II study of Imatinib mesylate (Glivec) treatment of patients with malignant peripheral nerve sheath tumors | ||
| Medical condition: malignant nerve sheath tumor | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-004230-40 | Sponsor Protocol Number: B1871006 | Start Date*: 2006-02-17 | |||||||||||
| Sponsor Name:Wyeth Pharmaceuticals Inc., a wholly owned subsidary of Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA | |||||||||||||
| Full Title: A Phase 1/2 Study of SKI-606 in Philadelphia Chromosme Positive Leukemias | |||||||||||||
| Medical condition: Philadelphia Chromosome positive leukemias occur as a result of a reciprocal translocation between chromosomes 9 and 22. Its most common phenotype is Chronic Myelogenous Leukemia (CML), which has ... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) ES (Completed) HU (Completed) AT (Completed) FI (Completed) SE (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-003774-40 | Sponsor Protocol Number: TheStopGISTtrial | Start Date*: 2016-11-09 | |||||||||||
| Sponsor Name:Oslo University Hospital | |||||||||||||
| Full Title: Discontinuation of imatinib in patients with oligo-metastatic gastrointestinal stromal tumor that has become radiologically undetectable with treatment | |||||||||||||
| Medical condition: Gastrointestinal stromal tumour (GIST) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: NO (Prematurely Ended) FI (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-000075-85 | Sponsor Protocol Number: I-StrokeII2016 | Start Date*: 2018-06-19 | ||||||||||||||||
| Sponsor Name:Karolinska Institutet | ||||||||||||||||||
| Full Title: A phase 3, randomised, double-blind, placebo-controlled, parallel-arm efficacy trial of Imatinib in acute ischaemic stroke | ||||||||||||||||||
| Medical condition: Patients with acute ischaemic stroke and an imaging scan excluding any intracranial haemorrhage | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: SE (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2010-022945-52 | Sponsor Protocol Number: ADVL0516 | Start Date*: 2012-01-26 | ||||||||||||||||
| Sponsor Name:Children’s Oncology Group | ||||||||||||||||||
| Full Title: A Phase 1 Study of BMS-354825 (Dasatinib) in Children with Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia. | ||||||||||||||||||
| Medical condition: Refractory solid tumors Ph+ leukemia | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: Outside EU/EEA | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2008-007054-35 | Sponsor Protocol Number: CAMN107A2404 | Start Date*: 2009-08-17 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A RANDOMIZED PHASE III STUDY OF IMATINIB DOSE OPTIMIZATION COMPARED WITH NILOTINIB IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA AND SUBOPTIMAL RESPONSE TO STANDARD-DOSE IMATINIB | |||||||||||||
| Medical condition: IMATINIB DOSE OPTIMIZATION COMPARED WITH NILOTINIB IN PATIENTS WITH CML AND SUBOPTIMAL RESPONSE TO STANDARD-DOSE IMATINIB | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) FI (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-005153-22 | Sponsor Protocol Number: CA180-043 | Start Date*: 2006-07-24 |
| Sponsor Name:Bristol-Myers Squibb International Corporation | ||
| Full Title: An open-label, randomized study of dasatinib vs. high-dose (800 mg) imatinib in the treatment of subjects with chronic phase chronic myeloid leukemia who have had a suboptimal response after at lea... | ||
| Medical condition: Subjects with Ph+ chronic phase Chronic Myeloid leukemia (CML) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Completed) FI (Completed) DK (Prematurely Ended) PT (Completed) BE (Completed) DE (Completed) GB (Completed) IT (Completed) ES (Completed) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
